Ranitidine
Breast Carcinoma In Situ
Ohio State University Comprehensive Cancer CenterSmall moleculePhase 2/3Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 95/ 100
Competitive context
16 Active assets in the Breast Carcinoma In Situ cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Exemestane Alliance for Clinical Trials in Oncology | Phase 4 | BBB |
Letrozole Alliance for Clinical Trials in Oncology | Phase 4 | BBB |
Tamoxifen Alliance for Clinical Trials in Oncology | Phase 4 | BB |
Anastrozole Alliance for Clinical Trials in Oncology | Phase 4 | BB |
Toremifene Fred Hutchinson Cancer Center | Phase 4 | BB |
View all 28 →
Same molecule, other indications
Ranitidine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →